Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 6/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 5/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27201481 | 0.83 | HRH4 (0.53) | MAP4K4LRRK2HRH4DOT1LBTK | |
| SCHEMBL30885318 | 0.83 | HRH4 (0.53) | MAP4K4LRRK2HRH4DOT1LBTK | |
| SCHEMBL30834277 | 0.82 | MAP4K4 (0.51) | MAP4K4LRRK2HRH4PIK3CABTK | |
| SCHEMBL27201438 | 0.82 | MAP4K4 (0.51) | MAP4K4LRRK2HRH4PIK3CABTK | |
| SCHEMBL27201410 | 0.81 | MAP4K4 (0.53) | MAP4K4LRRK2HRH4KCNH2HRH3 | |
| SCHEMBL30885255 | 0.80 | MAP4K4 (0.53) | MAP4K4LRRK2HRH4KCNH2HRH3 | |
| SCHEMBL27201579 | 0.80 | MAP4K4 (0.53) | MAP4K4LRRK2HRH4KCNH2HRH3 | |
| SCHEMBL27201514 | 0.80 | MAP4K4 (0.51) | MAP4K4LRRK2HRH4KCNH2HRH3 | |
| SCHEMBL27201336 | 0.80 | MAP4K4 (0.51) | MAP4K4LRRK2HRH4KCNH2HRH3 | |
| SCHEMBL30885232 | 0.78 | MAP4K4 (0.51) | MAP4K4LRRK2HRH4DPP4PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | claimed |
| WO-2024073502-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-04 | — | — | WO | claimed |
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132464-A1 | HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS | GID4, MDM2, XIAP | MAP4K4 1878/4885LRRK2 209/4885HRH4 4074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.